Loading...

ASMB ASSEMBLY BIOSCIENCES INC Expansion Plans 8-K Filing

SSMB

SMB

ASSEMBLY BIOSCIENCES INC

(ASMB)

2025 8-K

Financial Results Announced

Clinical Trial Results

Financial Results Report

Product Expansion

Financial Statements

Amendments to stock plans

Financial Statements

Financial Results

Clinical Study Results

Sublease Amendment

Clinical Study Results

Collaboration Update

Stock Sale Agreement

Financial Results

Clinical Study Update

Financial Results Announcement

Equity Financing Registered...

Stock Incentive Plan and Em...

Financial Results Announcement

Financial Results Announcement

Appointment and Bonus Plan ...

Reverse Stock Split

Special Meeting Results

Termination of License Agre...

Appointment, Headquarters C...

Earnings Reports

Collaboration Agreement wit...

Financial Results Announcement

Sublease Agreement

Annual Meeting Approval

Financial Results Announcement

Clinical Study Results

Financial Results and Clini...

External Links:

On December 8, 2025, Assembly Biosciences reported promising interim results from its Phase 1b studies for HSV inhibitors ABI-1179 and ABI-5366, with ABI-1179 showing a 98% reduction in HSV-2 shedding compared to placebo and ABI-5366 showing a 76% reduction. Both drugs appear well-tolerated, supporting further development.

AI Assistant

ASSEMBLY BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.